MICROBIOTIX
MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
MICROBIOME
Phage, Microbiome
& Beyond
MICROBIOTIX
MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
MICROBIOME
Phage, Microbiome
& Beyond
MICROBIOTA BANK
(Purpose: research)
By providing FMT fecal microbiota for CDI-targeted diseases to 26 university hospitals nationwide, it showed therapeutic effects in more than 90% of patients with severe chronic C. difficile infection. We have established microbiota banking through risk factor screening based on international guidelines. We supply FMT to hospitals across the nation for clinical use. It is a liquid or oral capsule that can be selected according to the patient’s condition and preference.
01
FECAL
MICROBIOTA BANK
In 2017, we established the fecal banking necessary for the development of microbiome-based treatments. Through a microbiota bank with independent and strict risk factor screening we have supplied microbiota to hospitals nationwide.
02
FECAL MICROBIOTA
CLINICAL SERVICE
About 1,000 people were screened through numerous fecal donations, and the secured fecal microbiota was provided to 26 university hospitals nationwide. It has been used in about 400 cases of severe chronic C. difficile (CDI) infection and has shown excellent therapeutic effect.
03
FECAL MICROBIOTA
FORM & BEYOND
A liquid or oral capsule can be selected according to the patient’s condition and preference. It can maximize the synergetic effect of microbiome treatments when used in conjunction with bacteriophages.
CUSTOS
PLATFORM
01 Cell Banking (Numerous Pathogens - Phages Interaction)
02 In-silico virulence optimization model
03 Microbiome modulation (Phageome)
04 QbD based CMC optimization
05 Phage & MIcrobiome gene modification
Our pipeline will be expanded rapidly through the analysis of 1,000 new pathogens per month and discovering effective phages to fight against them. (NGS/PCS analysis to phage vs. microbiome, taxonomy, healthy patient phage comparison) to discover candidate drug substances and build optimized CMC to produce through our GMP.
The Sea of Phages
THE PHAGEOME
Healthy people maintain a stable and balanced intestinal microbial ecosystem (microbiome). In other words, changes in the intestinal core bacteriophage and microbiome are delicately intertwined with human health (metabolites and immune system) Bacteriophages are used to balance and change intestinal microbiome through targeted bacterial removal, symbiosis with bacteria, and modulation.
HGP RATIO
Healthy Gut Phageome
62%
Healthy people share
of key phages
42%
Patients with Ulcerative
colitis share
of key phages
54%
Patients with Crohn’s
disease share
of key phages
논문출처 : Healthy human gut phageome Pilar Manrique, Benjamin Bolduc, Seth T. Walk, John van der Oost, Willem M. de Vos, Mark J. Young Proceedings of the National Academy of Sciences Sep 2016, 113 (37) 10400-10405; DOI: 10.1073/pnas.1601060113span>
FMT DONOR E-Mail : zoatk7103@microbiotix.net |
1. Men and women aged 20-49 (non-smokers)
2. Residents of Seoul or the Seoul Metropolitan area that can visit Severance Hospital
- Excluded : In the case when one does not pass the given questionnaire
Click the link below, fill out the questionnaire, and wait for further contact
When participating in this study, blood, breath, and fecal tests are performed free of charge.
Depending on the result, if it is acceptable, we are willing to provide a small honorarium
MICROBIOTIX
MicrobiotiX strives to develop treatments
for global intractable diseases such as multidrug-resistant
bacterial infections, autoimmune diseases and cancer
MICROBIOME
Phage, Microbiome
& Beyond
MICROBIOTA BANK (Purpose: research)
By providing FMT fecal microbiota for CDI-targeted diseases to 26 university hospitals nationwide, it showed therapeutic effects in more than 90% of patients with severe chronic C. difficile infection. We have established microbiota banking through risk factor screening based on international guidelines. We supply FMT to hospitals across the nation for clinical use. It is a liquid or oral capsule that can be selected according to the patient’s condition and preference.
01
FECAL MICROBIOTA
BANK
In 2017, we established the fecal banking necessary for the development of microbiome-based treatments. Through a microbiota bank with independent and strict risk factor screening we have supplied microbiota to hospitals nationwide.
02
FECAL MICROBIOTA
CLINICAL SERVICE
About 1,000 people were screened through numerous fecal donations, and the secured fecal microbiota was provided to 26 university hospitals nationwide. It has been used in about 400 cases of severe chronic C. difficile (CDI) infection and has shown excellent therapeutic effect.
03
FECAL MICROBIOTA
FORM & BEYOND
A liquid or oral capsule can be selected according to the patient’s condition and preference. It can maximize the synergetic effect of microbiome treatments when used in conjunction with bacteriophages.
CUSTOS
PLATFORM
01 Cell Banking (Numerous Pathogens - Phages Interaction)
02 In-silico virulence optimization model
03 Microbiome modulation (Phageome)
04 QbD based CMC optimization
05 Phage & MIcrobiome gene modification
CUSTOS PLATFORM
Our pipeline will be expanded rapidly through the analysis of 1,000 new pathogens per month and discovering effective phages to fight against them. (NGS/PCS analysis to phage vs. microbiome, taxonomy, healthy patient phage comparison) to discover candidate drug substances and build optimized CMC to produce through our GMP.
The Sea of Phages
THE PHAGEOME
Healthy people maintain a stable and balanced intestinal microbial ecosystem (microbiome). In other words, changes in the intestinal core bacteriophage and microbiome are delicately intertwined with human health (metabolites and immune system) Bacteriophages are used to balance and change intestinal microbiome through targeted bacterial removal, symbiosis with bacteria, and modulation.
HGP RATIO
Healthy Gut Phageome
Citation : Healthy human gut phageome Pilar Manrique, Benjamin Bolduc, Seth T. Walk, John van der Oost, Willem M. de Vos, Mark J. Young Proceedings of the National Academy of Sciences Sep 2016, 113 (37) 10400-10405; DOI: 10.1073/pnas.1601060113span>
62%
Healthy people share
of key phages
42%
Patients with Ulcerative colitis share
of key phages
54%
Patients with Crohn’s disease share
of key phages
FMT DONOR E-Mail : zoatk7103@microbiotix.net |
| Selection criteria | Men and women aged 20-49 (non-smokers) Residents of Seoul or the Seoul Metropolitan area that can visit Severance Hospital Excluded : In the case when one does not pass the given questionnaire |
| How to participate | Click the link below, fill out the questionnaire, and wait for further contact |
| Participation benefits | When participating in this study, blood, breath, and fecal tests are performed free of charge. Depending on the result, if it is acceptable, we are willing to provide a small honorarium |
MICROBIOTIX CO., LTD
IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)
TEL : 02. 6379. 2649
E-mail : mx@microbiotix.net
Copyright © MICROBIOTIX. All rights reserved.
INQUIRIES |
MICROBIOTIX CO., LTD
IT Mirae Tower, 33, Digital-ro 9-gil, Geumcheon-gu, Seoul (60-21 Gasan-Dong, #304)
TEL : 02. 6379. 2649 l E-mail : mx@microbiotix.net
Copyright © MICROBIOTIX. All rights reserved.